Recombinant monoclonal antibody to ERBB3. Elgemtumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, head and neck. It binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells.
Figure 1 Human Anti-Human ERBB3 Antibody (TAB-422CQ) in WB
Western blot analysis of TAB-422CQ was performed by loading Recombinant Human HER3/ERBB3 Protein ECD (his Tag).
TAB-422CQ incubation concentration: 2ng/μL.
The secondary antibody: HRP-Goat Anti-Human IgG (H+L)
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 3: Reducing Antigen (0.6 μg)
Figure 2 Human Anti-Human ERBB3 Antibody (TAB-422CQ) in ELISA
ELISA analysis of TAB-422CQ was performed by coating with Recombinant Human HER3/ERBB3 Protein ECD (his Tag).
The secondary antibody: HRP-Goat Anti-Human IgG (H+L)
Figure 3 Human Anti-Human ERBB3 Antibody (TAB-422CQ) in DB
Dot Blot analysis of TAB-422CQ was performed by coating with Recombinant Human HER3/ERBB3 Protein ECD (his Tag).
TAB-422CQ incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Goat Anti-Human IgG (H+L)
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Elgemtumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to ERBB3. Elgemtumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, head and neck. It binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1729-sdAb | Recombinant Anti-human ERBB3 VHH Single Domain Antibody | WB, ICC, ChiP, FA, ELISA | Llama VHH |
TAB-070CT | Llama Anti-ERBB3 Recombinant Single Domain Antibody (TAB-070CT) | FC, Block | Llama VHH |
PABC-556 | Recombinant Llama Anti-ERBB3 Single Domain Antibody (PABC-556) | ELISA, SPR | Llama VHH |
There are currently no Customer reviews or questions for TAB-422CQ. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-422CQ, RRID: AB_3111934)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.